FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process
Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standardsThe company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug processThe FDA…